Avacta Group (AVCT) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Mar 2016 07:00 AM
RNS
Avacta Establishes Scientific Advisory Board
25 Feb 2016 04:34 PM
RNS
Holding(s) in Company
24 Feb 2016 07:00 AM
RNS
Grant Funding Awarded
23 Feb 2016 10:54 AM
RNS
Hardman & Co Issues Research Report
23 Feb 2016 07:00 AM
RNS
Director's Dealing
17 Feb 2016 07:00 AM
RNS
Directors' Dealings and Issue of Equity
26 Jan 2016 08:05 AM
RNS
Share Consolidation
25 Jan 2016 03:35 PM
RNS
Result of Annual General Meeting
25 Jan 2016 07:01 AM
RNS
Pre-close trading update
25 Jan 2016 07:00 AM
RNS
Philippe Cotrel Appointed Chief Commercial Officer
21 Jan 2016 07:00 AM
RNS
Proposed Shareholder Consolidation
07 Jan 2016 07:00 AM
RNS
Posting of Annual Report & Accounts and AGM Notice
05 Jan 2016 07:00 AM
RNS
Issue of Equity
10 Dec 2015 07:00 AM
RNS
Appointment of Tony Gardiner as CFO
01 Dec 2015 04:44 PM
RNS
Holding(s) in Company
30 Nov 2015 07:00 AM
RNS
Issue of Equity
23 Nov 2015 07:00 AM
RNS
Issue of Equity
06 Nov 2015 10:56 AM
RNS
Holding(s) in Company
30 Oct 2015 07:00 AM
RNS
Issue of Equity
26 Oct 2015 07:00 AM
RNS
Final Results
19 Oct 2015 07:00 AM
RNS
Affimers improve disease resistance in plants
09 Oct 2015 07:00 AM
RNS
Robust performance of Affimers on Luminex platform
08 Oct 2015 07:00 AM
RNS
Notice of Results
17 Sep 2015 07:00 AM
RNS
Appoints Dr Mike Owen as Non-executive Director
10 Sep 2015 07:00 AM
RNS
Total Voting Rights
03 Sep 2015 07:00 AM
RNS
Issue of Equity
05 Aug 2015 10:00 AM
RNS
Holding(s) in Company
05 Aug 2015 07:00 AM
RNS
Holding(s) in Company
04 Aug 2015 10:18 AM
RNS
Issue of Equity
31 Jul 2015 10:42 AM
RNS
Result of General Meeting
23 Jul 2015 07:00 AM
RNS
Issue of Equity
15 Jul 2015 07:00 AM
RNS
Conditional Placing to Raise up to £22.0 Million
07 Jul 2015 08:00 AM
RNS
Board Change
07 Jul 2015 07:00 AM
RNS
Pre-Close Trading Update
20 May 2015 11:48 AM
RNS
Holding(s) in Company
19 May 2015 12:42 PM
RNS
Holding(s) in Company
18 May 2015 07:00 AM
RNS
Re Agreement
11 May 2015 07:00 AM
RNS
Issue of Equity
05 May 2015 07:01 AM
RNS
Issue of Equity
28 Apr 2015 07:00 AM
RNS
Half Yearly Report
08 Apr 2015 07:00 AM
RNS
Notice of Results
23 Mar 2015 07:00 AM
RNS
Drug discovery partnership
23 Mar 2015 07:00 AM
RNS
Issue of Equity
12 Feb 2015 07:00 AM
RNS
Sale of Optim Trade and Assets
09 Feb 2015 07:00 AM
RNS
Affimer Development Contract with Protatonce
23 Jan 2015 02:31 PM
RNS
Result of AGM
23 Jan 2015 07:00 AM
RNS
Trading Statement
16 Jan 2015 07:00 AM
RNS
Commercial Partnership in the Agri-bio Market
06 Jan 2015 07:00 AM
RNS
Issue of Equity
22 Dec 2014 07:00 AM
RNS
Posting of Annual Report & Accounts and AGM Notice

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics.

It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Avacta Group share price launched at 5,448p in 2003. 

UK 100